undamentalytics Newsletter
Sign in

Inmune Bio, Inc. revenue

Inmune Bio, Inc.'s revenue was $50,000 in fiscal 2025, up 257.1% on the year before. Since fiscal 2020 ($11,000) it has grown at a compound 35.4% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue00111813741551450
Growth on the year before———+>999%+106.6%−58.6%−91.0%+257.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Inmune Bio, Inc. $50,000 257.1% -48.9%
Lyell Immunopharma, Inc. $27,000 -55.0% -91.8%
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%

Compare with peers

Head to head: INMB vs LYELAIM vs INMBIBIO vs INMB

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmune Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmune Bio, Inc.